Needham & Company LLC Reiterates “Hold” Rating for Surmodics (NASDAQ:SRDX)

Surmodics (NASDAQ:SRDX)‘s stock had its “hold” rating restated by investment analysts at Needham & Company LLC in a research note issued to investors on Thursday,Benzinga reports.

Separately, StockNews.com began coverage on shares of Surmodics in a research report on Thursday. They set a “hold” rating for the company. Five investment analysts have rated the stock with a hold rating, According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $50.00.

Surmodics Stock Performance

SRDX traded up $0.06 during midday trading on Thursday, reaching $38.46. The company had a trading volume of 118,959 shares, compared to its average volume of 230,828. The business has a 50-day moving average price of $38.57 and a two-hundred day moving average price of $38.69. Surmodics has a 12-month low of $25.17 and a 12-month high of $42.44. The company has a debt-to-equity ratio of 0.25, a quick ratio of 3.22 and a current ratio of 3.98. The stock has a market cap of $548.82 million, a PE ratio of -47.48 and a beta of 1.20.

Hedge Funds Weigh In On Surmodics

Hedge funds have recently modified their holdings of the stock. Quest Partners LLC lifted its holdings in Surmodics by 107,100.0% in the 3rd quarter. Quest Partners LLC now owns 1,072 shares of the company’s stock valued at $42,000 after purchasing an additional 1,071 shares in the last quarter. SG Americas Securities LLC boosted its stake in shares of Surmodics by 14.7% in the 1st quarter. SG Americas Securities LLC now owns 5,138 shares of the company’s stock valued at $151,000 after buying an additional 660 shares during the period. Lazard Asset Management LLC boosted its stake in shares of Surmodics by 13.4% in the 1st quarter. Lazard Asset Management LLC now owns 5,679 shares of the company’s stock valued at $166,000 after buying an additional 673 shares during the period. BNP Paribas Financial Markets lifted its stake in Surmodics by 7.5% during the first quarter. BNP Paribas Financial Markets now owns 6,878 shares of the company’s stock worth $202,000 after purchasing an additional 481 shares during the last quarter. Finally, Hardin Capital Partners LLC purchased a new stake in Surmodics during the second quarter worth approximately $206,000. Institutional investors and hedge funds own 96.63% of the company’s stock.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).